Digest Network Come funziona
Network
/
Società
Io
Non verificato

Ionis Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

48 comunicati stampa

Guarda tutti i comunicati
21/01/2026
HIV, AIDS e malattie autoimmuni
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Industria
Cardiologia
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Web e Social Network
Eventi
Fiere
Salute
Biotecnologia
Scienza
Farmaceutica
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/12/2025
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/12/2025
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Industria
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
14/11/2025
Mercato del lavoro
Industria
Salute
Biotecnologia
Farmaceutica
Cardiologia
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/11/2025
Salute
Biotecnologia
Farmaceutica
Cardiologia
Finanza
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Eventi
Web e Social Network
Salute
Farmaceutica
Ionis to present at upcoming investor conferences
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/11/2025
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0